← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Vir Biotechnology, Inc. (VIR) 10-Year Financial Performance & Capital Metrics

VIR •
HealthcareBiotechnologyVaccines and Infectious Disease
AboutVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.Show more
  • Revenue $69M -7.6%
  • EBITDA -$456M +20.3%
  • Net Income -$438M +16.1%
  • EPS (Diluted) -3.16 +17.5%
  • Gross Margin 82.92% +115.2%
  • EBITDA Margin -665.65% +13.7%
  • Operating Margin -682.68% +13.7%
  • Net Margin -638.87% +9.2%
  • ROE -45.73% -20.0%
  • ROIC -40.27% -14.2%
  • Debt/Equity 0.24 +187.0%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y0.39%
3Y-65.12%
TTM-7.61%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM16.09%

EPS CAGR

10Y-
5Y-
3Y-
TTM17.28%

ROCE

10Y Avg-26.52%
5Y Avg-7.65%
3Y Avg-38.51%
Latest-42.76%

Peer Comparison

Vaccines and Infectious Disease
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CVACCureVac N.V.1.05B4.666.478.96%37.93%33.02%7.95%0.06
NVAXNovavax, Inc.1.67B10.143.9364.69%39.19%
SCNIScinai Immunotherapeutics Ltd.3.03B0.890.15401.83%58.65%0.21
TNXPTonix Pharmaceuticals Holding Corp.142.05M13.97-0.0829.94%-9.63%-42.93%0.04
INOInovio Pharmaceuticals, Inc.65.34M1.81-0.46-73.83%-592.82%-115.42%0.17
IVVDInvivyd, Inc.362.35M1.69-1.18-119.63%-64.32%0.02
SPROSpero Therapeutics, Inc.122.2M2.17-1.71-53.77%-122.56%-165.46%0.09
AVIRAtea Pharmaceuticals, Inc.365.63M4.68-2.34-46.56%0.00

Compare VIR vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs BNTX

Compare head-to-head with BioNTech SE

vs MRNA

Compare head-to-head with Moderna, Inc.

Compare Top 5

vs BNTX, MRNA, SMMT, PCVX

Profit & Loss

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales/Revenue+149K868K711K67.25M1.1B1.62B86.18M74.2M68.56M
Revenue Growth %-482.55%-18.09%9357.81%1528.99%47.51%-94.67%-13.9%-7.61%
Cost of Goods Sold+62.51M100.23M00513.87M620.97M572.83M478.64M11.71M
COGS % of Revenue41954.36%11547.12%--46.91%38.43%664.69%645.03%17.08%
Gross Profit+-62.36M-99.36M711K67.25M581.54M994.83M-486.65M-404.44M56.85M
Gross Margin %-41854.36%-11447.12%100%100%53.09%61.57%-564.69%-545.03%82.92%
Gross Profit Growth %--59.33%100.72%9357.81%764.81%71.07%-148.92%16.89%114.06%
Operating Expenses+81.65M119.56M178.69M364.23M160.79M161.76M197.66M182.72M524.87M
OpEx % of Revenue54795.97%13774.19%25132.21%541.64%14.68%10.01%229.35%246.24%765.61%
Selling, General & Admin21.69M29.13M37.6M70.94M000092.07M
SG&A % of Revenue14559.06%3356.11%5288.05%105.49%----134.3%
Research & Development62.51M100.23M148.47M302.41M448.01M474.65M579.72M506.5M432.8M
R&D % of Revenue41954.36%11547.12%20882.14%449.72%40.9%29.38%672.69%682.57%631.3%
Other Operating Expenses83K-212K-7.38M-9.12M-287.21M-312.89M-382.06M-323.77M0
Operating Income+-81.5M-118.69M-177.98M-296.98M420.75M833.07M-684.3M-587.16M-468.02M
Operating Margin %-54695.97%-13674.19%-25032.21%-441.64%38.41%51.56%-794.04%-791.27%-682.68%
Operating Income Growth %--45.64%-49.95%-66.86%241.68%98%-182.14%14.2%20.29%
EBITDA+-81.06M-115.94M-173.46M-291.54M426.56M839.85M-664.85M-572.61M-456.34M
EBITDA Margin %-54406.04%-13356.68%-24396.91%-433.55%38.94%51.98%-771.47%-771.65%-665.65%
EBITDA Growth %--43.02%-49.62%-68.07%246.31%96.89%-179.16%13.87%20.3%
D&A (Non-Cash Add-back)432K2.76M4.52M5.44M5.81M6.78M19.45M14.56M11.68M
EBIT-81.5M-118.69M-177.98M-296.98M420.75M833.07M-661.09M-523.47M-437.77M
Net Interest Income+638K2.54M8.51M2.84M439K28.09M86.99M71.81M40.24M
Interest Income638K2.54M8.51M2.84M439K28.09M86.99M71.81M40.24M
Interest Expense000000000
Other Income/Expense721K2.33M3.45M-1.63M129.05M-78.79M56.11M64.06M30.25M
Pretax Income+-80.78M-116.36M-174.53M-298.61M549.8M754.28M-628.19M-523.11M-437.77M
Pretax Margin %-54212.08%-13405.99%-24546.98%-444.06%50.19%46.68%-728.93%-704.95%-638.56%
Income Tax+-10.92M-480K154K54K21.22M238.44M-13.08M-1.15M217K
Effective Tax Rate %86.48%99.59%100.09%100.02%96.14%68.39%97.91%99.78%100.05%
Net Income+-69.85M-115.88M-174.68M-298.67M528.58M515.84M-615.06M-521.96M-437.99M
Net Margin %-46880.54%-13350.69%-24568.64%-444.14%48.25%31.92%-713.69%-703.4%-638.87%
Net Income Growth %--65.9%-50.74%-70.98%276.98%-2.41%-219.24%15.14%16.09%
Net Income (Continuing)-69.85M-115.88M-174.68M-298.67M528.58M515.84M-615.12M-521.96M-437.99M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)+-10.02-1.20-1.62-2.513.963.83-4.59-3.83-3.16
EPS Growth %-88.02%-35%-54.94%257.77%-3.28%-219.84%16.56%17.49%
EPS (Basic)-10.02-1.20-1.62-2.514.073.89-4.59-3.83-3.16
Diluted Shares Outstanding6.97M96.91M107.65M119.16M133.44M134.81M134.13M136.25M138.52M
Basic Shares Outstanding6.97M96.91M107.65M119.16M129.88M132.61M134.13M136.25M138.52M
Dividend Payout Ratio---------

Balance Sheet

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Current Assets+192.35M117.78M403M772.37M1.56B2.52B1.59B1.04B514.08M
Cash & Short-Term Investments187.92M98.44M383.44M736.86M708.14M2.4B1.52B905.35M462.86M
Cash Only187.92M47.6M109.33M436.57M347.81M848.63M241.58M222.95M234.11M
Short-Term Investments050.84M274.1M300.29M360.33M1.55B1.28B682.4M228.75M
Accounts Receivable0000773.08M0003.6M
Days Sales Outstanding----257.6---19.17
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets010.76M6.18M7.99M8.59M59.2M65.82M137.11M47.62M
Total Non-Current Assets+59.22M73.81M109.04M146.4M391.45M283.01M330.83M356.33M488.74M
Property, Plant & Equipment5.14M12.29M16.31M79.89M130.05M188.17M167.2M122.86M117.72M
Fixed Asset Turnover0.03x0.07x0.04x0.84x8.42x8.59x0.52x0.60x0.58x
Goodwill16.94M16.94M16.94M16.94M16.94M16.94M16.94M16.94M16.94M
Intangible Assets35.88M36.92M35.66M33.82M33.29M32.76M22.57M8.1M7.85M
Long-Term Investments1M7.67M24.29M0201.39M23.93M105.28M190.01M314.57M
Other Non-Current Assets1.26M7.67M15.85M15.75M9.78M-228.5M18.86M18.42M31.66M
Total Assets+251.57M191.6M512.07M918.76M1.95B2.8B1.92B1.4B1B
Asset Turnover0.00x0.00x0.00x0.07x0.56x0.58x0.04x0.05x0.07x
Asset Growth %--23.84%167.27%79.42%112.71%43.38%-31.51%-27.11%-28.31%
Total Current Liabilities+12.44M39.91M59.21M99.06M341.24M511.03M175.41M119.66M92.81M
Accounts Payable4.9M6.47M5.88M5.08M6.52M6.42M6.33M5.08M9.8M
Days Payables Outstanding28.623.57--4.633.774.043.87305.66
Short-Term Debt000000008.8M
Deferred Revenue (Current)08.76M6.18M6.45M98.21M15.52M64.85M12.65M0
Other Current Liabilities022.02M22.08M10.6M07.65M9.35M16.06M74.21M
Current Ratio15.46x2.95x6.81x7.80x4.58x4.93x9.05x8.71x5.54x
Quick Ratio15.46x2.95x6.81x7.80x4.58x4.93x9.05x8.71x5.54x
Cash Conversion Cycle---------
Total Non-Current Liabilities+308.04M330.87M28.92M102.84M181.18M213.1M153.42M128.77M144.73M
Long-Term Debt0000000089.05M
Capital Lease Obligations00066.56M133.56M123.84M111.67M90.14M89.05M
Deferred Tax Liabilities3.31M3.31M3.31M3.25M18.44M3.25M000
Other Non-Current Liabilities10.4M10.84M12.95M29.22M25.36M32.8M40.22M38.63M-33.38M
Total Liabilities320.48M370.77M88.13M201.91M522.42M724.13M328.82M248.43M237.55M
Total Debt+010.14M237K70.18M137.49M127.97M124.54M97.89M186.91M
Net Debt-187.92M-37.46M-109.1M-366.39M-210.33M-720.66M-117.04M-125.06M-47.2M
Debt / Equity--0.00x0.10x0.10x0.06x0.08x0.09x0.24x
Debt / EBITDA----0.32x0.15x---
Net Debt / EBITDA-----0.49x-0.86x---
Interest Coverage---------
Total Equity+-68.92M-179.18M423.94M716.85M1.43B2.08B1.59B1.15B765.28M
Equity Growth %--159.99%336.61%69.09%99.74%45.12%-23.47%-27.66%-33.48%
Book Value per Share-9.88-1.853.946.0210.7315.4111.868.445.52
Total Shareholders' Equity-68.92M-179.18M423.94M716.85M1.43B2.08B1.59B1.15B765.28M
Common Stock1K1K11K13K13K13K13K14K14K
Retained Earnings-77.95M-193.84M-368.52M-667.18M-138.6M377.24M-237.82M-759.78M-1.2B
Treasury Stock0-14.67M0000000
Accumulated OCI-292.52M-14K-601K-1.28M-1.1M-9.12M-815K-1.72M-2.06M
Minority Interest000000000

Cash Flow

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operations+-66.38M-94.1M-129.63M-190.94M-47.59M1.66B-778.78M-446.35M-391.78M
Operating CF Margin %-44551.01%-10840.55%-18232.35%-283.95%-4.34%102.94%-903.67%-601.51%-571.48%
Operating CF Growth %--41.75%-37.77%-47.29%75.08%3595.04%-146.82%42.69%12.23%
Net Income-69.85M-115.88M-174.68M-298.67M528.58M515.84M-615.06M-521.96M-437.99M
Depreciation & Amortization432K2.76M4.52M5.44M5.81M6.78M19.45M14.56M21.15M
Stock-Based Compensation4.78M5.05M8.72M27.6M83.78M102.08M078.46M49.07M
Deferred Taxes-10.92M-480K0-52K15.19M-15.19M-1.06M-2.95M0
Other Non-Cash Items4.32M1.97M23.61M45.21M-52.56M388.37M122.48M69.55M-1.57M
Working Capital Changes4.86M12.49M8.2M29.52M-628.39M665.37M-304.59M-84.01M-22.45M
Change in Receivables0000-773.08M770.04M-565K-6.51M0
Change in Inventory000052.81M0000
Change in Payables2.01M1.47M964K-790K-171K797K732K-988K5M
Cash from Investing+-29.99M-60.44M-256.16M-9.86M-140.81M-1.19B164.73M499.37M310.37M
Capital Expenditures-2.74M-8.19M-8.94M-6.55M-21.82M-68.01M-21.57M-7.3M-4.83M
CapEx % of Revenue1840.27%943.78%1257.38%9.74%1.99%4.21%25.03%9.84%7.05%
Acquisitions-27.25M25K00140.81M0100K3.37M253K
Investments---------
Other Investing0-1.74M0180K-140.81M0000
Cash from Financing+271.18M24.98M449.24M529.47M100.33M34.76M7.38M4.39M3.79M
Debt Issued (Net)004.37M-250K-259K-260K-287K-165K-361K
Equity Issued (Net)1000K1000K1000K1000K1000K1000K1000K1000K1000K
Dividends Paid000000000
Share Repurchases00-3K000000
Other Financing0584K1.13M-189K15.38M6.56M-100K00
Net Change in Cash174.81M-129.56M63.45M328.67M-88.07M504.55M-606.47M57.4M-77.63M
Free Cash Flow+-69.12M-102.29M-138.57M-197.49M-69.41M1.6B-800.36M-453.65M-396.61M
FCF Margin %-46391.28%-11784.33%-19489.73%-293.69%-6.34%98.73%-928.71%-611.35%-578.52%
FCF Growth %--47.98%-35.47%-42.52%64.86%2398.43%-150.17%43.32%12.57%
FCF per Share-9.91-1.06-1.29-1.66-0.5211.83-5.97-3.33-2.86
FCF Conversion (FCF/Net Income)0.95x0.81x0.74x0.64x-0.09x3.22x1.27x0.86x0.89x
Interest Paid000000000
Taxes Paid00000252.03M0786K0

Key Ratios

Metric201720182019202020212022202320242025
Return on Equity (ROE)---142.74%-52.36%49.2%29.39%-33.53%-38.09%-45.73%
Return on Invested Capital (ROIC)---271.84%-66.96%40.15%48.46%-36.26%-35.25%-40.27%
Gross Margin-41854.36%-11447.12%100%100%53.09%61.57%-564.69%-545.03%82.92%
Net Margin-46880.54%-13350.69%-24568.64%-444.14%48.25%31.92%-713.69%-703.4%-638.87%
Debt / Equity--0.00x0.10x0.10x0.06x0.08x0.09x0.24x
FCF Conversion0.95x0.81x0.74x0.64x-0.09x3.22x1.27x0.86x0.89x
Revenue Growth-482.55%-18.09%9357.81%1528.99%47.51%-94.67%-13.9%-7.61%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.